Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ono’s Q1 Operating Profit Up 35% as SGA, R&D Costs Decrease on COVID-19
Ono Pharmaceutical saw its April-June group operating profit surge 35% year on year as a spate of seminar cancellations and restrained sales activities due to the COVID-19 crisis resulted in decreases in SGA costs and R&D spending. According to its…
To read the full story
Related Article
- Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
- Ono’s Profits Slide Over 60% as Deciphera Buyout Costs Swell
May 9, 2025
- Ono’s H1 Revenue Falters 7% after Opdivo Price Cuts
November 1, 2024
- Ono Crosses 500 Billion Yen in FY2023 Sales, Forxiga Drives 9th Year of Growth
May 10, 2024
- Ono Posts Record High H1 Earnings for 6th Consecutive Year Driven by Opdivo
November 2, 2023
- Ono Scores 12.5% Rise in Q1 Revenue on Opdivo, Forxiga
August 1, 2023
- Opdivo’s Japan Patent to Expire in 2031, Ono to Cover LOE with New Launches: Chief
May 11, 2023
- Ono Notches Two-Digit Growth in FY2022; Opdivo en Route to 150 Billion Yen Mark
May 11, 2023
- Ono’s 9-Month Revenue Climbs 25% on Robust Opdivo and Forxiga Sales
February 1, 2023
- Ono’s April-September Sales Zoom 24.5% on Bullish Opdivo and Forxiga
November 1, 2022
- Ono Logs Two-Digit Growth in Q1 Earnings on Opdivo
August 2, 2022
- Ono Nets 16.8% Sales Growth on Opdivo, Forxiga; 400 Billion-Plus Yen Eyed for FY2022
May 12, 2022
- Buoyant Opdivo and Forxiga Drive Ono’s Growth in April-December
February 1, 2022
- Ono Enjoys Double-Digit Growth in H1 on Upbeat Opdivo, Forxiga
November 2, 2021
- Ono Nets 5.8% Revenue Growth in FY2020 on Opdivo, Forxiga
May 12, 2021
- Ono Logs 4.3% Sales Growth in April-December, Opdivo Jumps
February 2, 2021
- Ono’s FY2019 Sales Up 1.3% on Keytruda-Tied Royalties
May 13, 2020
BUSINESS
- Kidswell, Treehill to Form US Firm for Cell Therapy Development
February 17, 2026
- Ono’s Velexbru Accepted for FDA Review in PCNSL
February 17, 2026
- Celltrion Sets April 28 Launch Date for Japan’s 1st Actemra Biosimilar
February 17, 2026
- Nxera Cuts Executive Pay as Losses Widen
February 16, 2026
- Otsuka Pharma Sales Rise 7.1% in 2025, Driven by Rexulti
February 16, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…